Clinical trials aimed at refining the dosage of the vaccine once morest monkeypox will start at UNITED STATES, announced this Thursday the American health authorities, once morest a backdrop of uncertainty as to the effectiveness of this new remedy. The study, which will bring together more than 200 patient volunteers between the ages of 18 and 50, from different US states, is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and aims to assess the immune response depending on the amount of vaccine received and how it is administered.
The vaccine concerned, produced by the Danish laboratory Bavarian Nordic, is authorized by the American authorities within the framework of prevention campaigns once morest smallpox and monkeypox in persons 18 years of age or older. These trials will not aim to determine the effectiveness of the vaccine. They will aim in particular to collect information on the safety and tolerance corresponding to different dosages “which would make it possible to expand the current offer of vaccines”, declared in a press release Anthony Fauci, the director of the National Institute of Allergies and Diseases. infectious.
Scientists will test immune response spikes and compare side effects between three separate groups of patients. The monkeypox virus causes painful skin lesions and symptoms similar to those of flu. Most people recover completely, but it can lead to serious complications, including bacterial infections. President Joe Biden relies heavily on this vaccine to stem the monkeypox epidemic, which has affected more than 20,000 people in the United States since May.
